Picture of Catalyst Pharmaceuticals logo

CPRX Catalyst Pharmaceuticals Income Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapHigh Flyer

Annual income statement for Catalyst Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Revenue
Total Revenue102119141214398
Cost of Revenue
Gross Profit87.5102119180346
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Total Operating Expenses70.577.888.4112311
Operating Profit31.841.352.410286.8
Other Net Non Operating Costs
Net Income Before Taxes33.441.952.710594.5
Provision for Income Taxes
Net Income After Taxes31.97539.583.171.4
Net Income Before Extraordinary Items
Net Income31.97539.583.171.4
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income31.97539.583.171.4
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS0.3010.7060.3660.7460.628